Q-omics provides the consensus-scored MIR1293 profile across patient tissues and cancer cell-line models. MIR1293 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR1293 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR1293 RNA expression shows 7,001 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LIHC, BRCA, and ESCA as cancer lineages where MIR1293 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1293 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1293 survival associations across molecular data types. MIR1293 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1293 RNA expression–survival associations across cancer types. High MIR1293 expression shows unfavorable associations in LIHC, PCPG, UCEC and LUAD, but favorable associations in LAML and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR1293 RNA expression.
This table summarizes MIR1293 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1293. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1293 shows lower tumor expression in KICH and higher tumor expression in BRCA, STAD and BLCA. The BRCA box plot shows higher MIR1293 RNA expression in tumor versus normal tissue (log2 FC = +0.835, t-test p < 0.001).
This table shows molecular features associated with MIR1293 in patient tissues and cancer cell lines. In patient samples, MIR1293 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
